Business Overview (Details) $ in Millions			1 Months Ended	3 Months Ended
	Jan. 14, 2022 USD ($)	Feb. 14, 2014 USD ($)	Oct. 31, 2018 USD ($) shares	Dec. 31, 2018 USD ($) shares	Feb. 14, 2014 CAD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Threshold milestone payment payable					$ 2.5
Merger Agreement, Upon Receipt of Phase II Positive Data
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares to be issued | shares			4,317
Additional milestone payments payable			$ 3,000,000
Merger Agreement, Upon Receipt of Phase II Positive Data | Subsequent Event
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additional milestone payments payable	$ 3,000,000
Merger Agreement, Upon Initiation of Phase III Trial
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additional milestone payments payable			5,000,000
Merger Agreement, Upon Initiation of Phase III Trial | Subsequent Event
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additional milestone payments payable	5,000,000
Merger Agreement, Upon Acceptance By FDA of New Drug
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additional milestone payments payable			8,000,000
CEO
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
First milestone payment			$ 300,000
Number of shares issued | shares			603
CEO | Subsequent Event
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
First milestone payment	800,000
Petrus Wijngaard, Director of Company
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
First milestone payment			$ 2,805
Number of shares issued | shares			6
Hepion Employees [Member] | Subsequent Event
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
First milestone payment	200,000
Ciclofilin
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
First milestone payment			$ 700,000	$ 1,000,000
Number of shares issued | shares			1,439	1,439
Issuance of common stock in conjunction with milestone payment			$ 100,000	$ 55,398
Percentage of issued and outstanding			2.50%	2.50%
Percentage of proceeds from liquidity event		30.00%
Ciclofilin | Subsequent Event
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
First milestone payment	$ 2,000,000
Percentage of issued and outstanding	7.50%
Ciclofilin | Merger Agreement, Upon Positive Analysis of Phase IIb Trial | Subsequent Event
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additional milestone payments payable	$ 1,000,000
Ciclofilin | Merger Agreement, Upon Acceptance By FDA of New Drug | Subsequent Event
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additional milestone payments payable	5,000,000
Ciclofilin | Merger Agreement Upon Approval by FDA Of New Drug | Subsequent Event
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additional milestone payments payable	$ 8,000,000
Aurinia
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
First milestone payment			$ 300,000
Threshold milestone payment payable					0.5
Offset payment, amount					2.0
Percentage of royalty on net sales		2.50%
Royalty percentage		5.00%
Amount payable from the proceeds of liquidity event		$ 200,000
Threshold amount payable					$ 5.0